Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and PTC Therapeutics (PTCTResearch Report) with bullish sentiments.

PTC Therapeutics (PTCT)

In a report issued on June 10, Raju Prasad from William Blair maintained a Buy rating on PTC Therapeutics. The company’s shares closed last Friday at $28.41, close to its 52-week low of $25.01.

According to, Prasad has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.9% and a 36.8% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $49.43, representing an 82.5% upside. In a report issued on June 2, J.P. Morgan also maintained a Buy rating on the stock with a $63.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PTCT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More